|1.||Rabasseda, X: 3 articles (01/2007 - 05/2005)|
|2.||Prous, J R: 3 articles (01/2007 - 05/2005)|
|3.||Bayés, M: 2 articles (01/2007 - 01/2006)|
|4.||Min, Yang Won: 1 article (05/2015)|
|5.||Rhee, Poong-Lyul: 1 article (05/2015)|
|6.||Shahbazian, Anaid: 1 article (11/2009)|
|7.||Holzer, Peter: 1 article (11/2009)|
|8.||Painsipp, Evelin: 1 article (11/2009)|
|9.||Lackner, Jeffrey M: 1 article (02/2008)|
|10.||Fayyaz, Mohammad: 1 article (02/2008)|
10/01/2007 - "Results from preclinical and two dose-finding studies have suggested that cilansetron could be effective in the treatment of patients with diarrhea-predominant irritable bowel syndrome. "
10/01/2007 - "Further trials are underway to fully determine the role of cilansetron in the treatment of diarrhea-predominant irritable bowel syndrome."
10/01/2005 - "In phase III trials, cilansetron has been shown to be efficacious for the relief of a wide spectrum of symptoms related to irritable bowel syndrome with diarrhea both in male and female patients. "
10/01/2007 - "Cilansetron in the treatment of diarrhea-predominant irritable bowel syndrome?"
10/01/2005 - "Because of its high degree of efficacy, the fact that it is well tolerated by the overwhelming majority of patients and that it shows efficacy in both genders, cilansetron represents a major advance in the treatment of irritable bowel syndrome with diarrhea predominance."
|2.||Irritable Bowel Syndrome (Syndrome, Irritable Bowel)
01/01/2005 - "According to Solvay's first half 2004 results, cilansetron is due to begin phase II clinical trials in Japan for the treatment of irritable bowel syndrome with diarrhoea predominance."
02/01/2005 - "Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea."
01/01/2005 - "In April 2005, Solvay Pharmaceuticals received a 'not-approvable' action letter from the US FDA on its NDA for cilansetron for the treatment of irritable bowel syndrome with diarrhoea predominance (IBS-D), in both men and women. "
01/01/2005 - "In April 2004, Solvay Pharmaceuticals submitted a new drug application (NDA) for cilansetron in the UK (for the European Union) for the treatment of irritable bowel syndrome with diarrhoea predominance, in both men and women. "
01/01/2005 - "Cilansetron [KC 9946] is a serotonin-3 receptor (5-HT(3)) antagonist under development with Solvay Pharmaceuticals for the treatment of irritable bowel syndrome with diarrhoea predominance (IBS-D), in both men and women.5-HT(3) antagonists inhibit the 5-HT(3) receptors, resulting in decreased GI motility, secretion and sensation, thereby improving symptoms of IBS-D. "
02/01/2005 - "The most commonly reported side effect with cilansetron has been constipation and, in general, the drug has been well tolerated in clinical trials. "
10/01/2005 - "The most common side effect of cilansetron is constipation, which is seen in 3-12% of subjects at 6 months. "
10/01/2007 - "Cilansetron tended to induce constipation but, apart from transient ischemic colitis in four out of 1484 cases, no serious adverse effects were observed. "
05/01/2015 - "However, alosetron was voluntarily withdrawn due to postmarketing reports of ischemic colitis and complications of constipation, and cilansetron was never marketed. "
11/01/2007 - "Among the serotonergic drugs, serotonin 5-HT4 receptors agonists (tegaserod) may be available soon, but the development of 5-HT3 antagonists (alosetron, cilansetron) has been stopped for safety reasons (ischemic colitis and severe constipation). "
02/01/2005 - "The event rate for suspected ischaemic colitis associated with cilansetron from clinical trials is 3.77 per 1000 person years of exposure. "
02/01/2005 - "All of the cases of suspected ischaemic colitis reported with cilansetron have resolved without serious sequelae. "
02/01/2005 - "Although rare, the most concerning side effect observed with cilansetron has been suspected ischaemic colitis. "
11/01/2009 - "As the use of the 5-HT(3) receptor antagonist alosetron (GlaxoSmithKline) and the 5-HT(4) receptor agonist tegaserod (Novartis) in patients with irritable bowel syndrome has been associated with cases of ischaemic colitis, the effects of alosetron, cilansetron (Solvay) and tegaserod on the rat splanchnic circulation were evaluated. "
|5.||Abdominal Pain (Pain, Abdominal)
|2.||5-HT3 Serotonin Receptors (5 HT3 Receptor)
|7.||Serotonin 5-HT3 Receptor Antagonists
|9.||Serotonin (5 Hydroxytryptamine)
|1.||Nebulizers and Vaporizers (Inhaler)